Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Balancing immunosuppressive treatment in organ transplantation in order to achieve effective
prevention of rejection on one side and avoidance of negative side effects on the other side
is a major challenge, leading to developing different immunosuppressive protocols.
Cornerstones of immunosuppressive treatment such as Corticosteroids (CS) and Calcineurin
Inhibitors (CNI) are known to cause an increased incidence of diabetes, cardiovascular
morbidity, nephrotoxicity and malignancies.
The investigators believe that both avoidance of CS and minimization of CNI, while using
Anti-ThymocyteGlobuline(ATG) induction (instead of interleucin-2 receptor blockers) and
mycofenolate mofetil(MMF) therapeutic drug monitoring is going to reduce negative side
effects, without increased rejection frequency in renal transplanted patients.